A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Exclusion Criteria

• •1. High grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia.
• •2. High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden.
• •3. Symptomatic central nervous system involvement.
• •4. Impaired cardiac function or clinically significant cardiac disease.
• •5. Prior Red blood cell (RBC) transfusion \< 3 months prior to starting CC-90002 (Part A only).
• •6. Prior autologous stem cell transplant ≤ 3 months prior to starting CC-90002.
• •7. Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-90002.
• •8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90002, whichever is shorter.
• •9. Major surgery ≤ 2 weeks prior to starting CC-90002.
• •10. Pregnant or nursing females.
• •11. Known HIV infection.
• •12. Known chronic, active hepatitis B or C (HBV/HCV) infection.
• •13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
• •14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
• •15. History of concurrent second cancers requiring active, ongoing systemic treatment.
• •concurrent second cancers requiring active, ongoing systemic treatment.